Connecticut Medicaid spending on GLP-1 drugs

How much did Connecticut Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $202.8 million for GLP-1 drugs paid through Connecticut Medicaid in 2025, across at least 174,553 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 21 rows of 141, so these figures are floors.

Pharmacies were reimbursed at least $45.1 million for GLP-1 drugs paid through Connecticut Medicaid in 2026 (quarter 1 only, as posted so far), across at least 35,591 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 9 rows of 40, so these figures are floors.

By year and ingredient

2020at least $14,532,075No data$13,536,645at least $12,734,447at least $1,607,352$188,540$644,370at least $43,243,429
2021at least $25,046,312No data$12,004,751$23,979,509at least $975,062$252,193$522,334at least $62,780,161
2022at least $48,036,165at least $1,466,529$10,006,984$44,062,627at least $518,668$210,196$355,066at least $104,656,237
2023at least $111,667,553$20,984,082$6,433,070$42,779,667at least $325,052$131,459$258,453at least $182,579,336
2024at least $174,859,867at least $49,805,054at least $1,903,078$23,804,181at least $114,772$119,945$122,062at least $250,728,960
2025at least $121,987,117at least $64,572,126at least $407,814$15,695,498Suppressed$72,493at least $79,003at least $202,814,053
2026 (Q1)at least $22,887,100$19,001,463at least $39,488$3,175,392No data$13,646Suppressedat least $45,117,089

By product, 2025

Ozempicat least $114,671,186at least 101,8532 of 15
Rybelsusat least $4,426,442at least 3,0831 of 13
Wegovyat least $2,889,489at least 2,1253 of 20
Mounjaro$60,824,87150,3270 of 24
Zepboundat least $3,747,255at least 3,3502 of 14
Liraglutide (generic name listing)at least $134,890at least 2499 of 20
Victoza$272,9253560 of 8
Trulicity$15,695,49813,0870 of 16
BydureonSuppressedSuppressed2 of 2
ByettaSuppressedSuppressed1 of 1
Soliqua$72,493730 of 4
Xultophyat least $79,003at least 501 of 4

By quarter, 2025

Q1 2025at least $56,503,424at least 51,0067 of 33
Q2 2025at least $55,733,753at least 48,6404 of 32
Q3 2025at least $47,733,992at least 40,2064 of 38
Q4 2025at least $42,842,884at least 34,7016 of 38

By quarter, 2026 (posted so far)

Q1 2026at least $45,117,089at least 35,5919 of 40

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.